How many investments has Bios Partners made?

Bios Partners has 19 tracked investments, 9 of which have exited, including 1 dated in the last 24 months.

What stage does Bios Partners invest at?

Bios Partners invests at the Seed, Series A, Series B, Series C, Growth stages.

What sectors does Bios Partners focus on?

Bios Partners focuses on Biotech, Healthtech, Medical Devices.

Where is Bios Partners located?

Bios Partners is headquartered in Fort Worth, US.

Bios Partners

Venture capitaloperating company · company profile

Fort Worth · Seed–Growth · 15 people tracked

Also known as BIOS CAPITAL MANAGEMENT, LP · STEELHEAD CAPITAL MANAGEMENT, LLC

★ Follow + Add to CRM ⤳ Find an introduction

Find your way into Bios Partners

Paths you didn't know you had: your email and LinkedIn already hold routes to the Bios Partners team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

✨ Fox Verdict

Investment thesis

Bios Partners argues that scientific talent is distributed evenly across the country while venture capital concentrates on the coasts, particularly Silicon Valley and the Northeastern US. The firm seeks to disrupt this 'geographic favoritism' by investing in scientifically compelling opportunities in the Central US that are typically overlooked and undervalued. Its approach centers on company cultivation and is driven by science, drawing on a team with combined experience across hedge funds, private equity, clinical drug development, and public pharma/biotech analysis.

Invests inBiotech Healthtech Medical Devices Fort Worth United States

Source: firm website, verified Sep 29, 2026.

Leave your own feedback

Stage

Seed–Growth

Fort Worth, Texas, US

Instruments

Equity

Founded

2014

AUM

$202.5M

Tracked investments

IPOs

Acquisitions

Team · 15 people

from the firm's website & curated & public directories

Leslie W. Kreis, Jr.· Managing Partner & Co-Founder

Has over 25 years of public and private equity investing experience, is Managing Principal at Steelhead Capital Management, and a founding member of Cowtown Angels. Previously a VP at HBK Investments managing a $3B global portfolio. BBA in Finance from TCU.

lkreis@biospartners.com

Aaron G.L. Fletcher· Managing Partner· Fort Worth, Texasin

Managing director of Bios Partners and founder/president of Bios Research, providing healthcare public equity research. Holds a PhD in biochemistry from Colorado State University and is a visiting professor at Dallas Baptist University with 10+ years in biotech/healthcare equity consulting.

afletcher@biospartners.com

Amanda de la Garza· Partner· Dallas, Texasin

Has over five years of financial and scientific analysis experience as an analyst at Bios Research and Bios Partners. Holds a BS in Biology and an MPH in epidemiology and global health, and is pursuing a PhD in Leadership Studies.

adelagarza@biospartners.com

John Fucci· Partner· Fort Worth, Texasin

Partner at Bios Partners focused on diligence, negotiations, portfolio management, and investor relations. Serves on the board of Lantern Pharma and was previously a VP at Steelhead Capital Management. Double majored in Finance and Entrepreneurial Management at TCU.

jfucci@biospartners.com

Stella Robertson· Partner· Fort Worth, Texasin

Co-founder of Bios Partners with 25+ years in pharmaceutical R&D. Former VP of R&D at Alcon Laboratories overseeing the ophthalmic pipeline. Holds a PhD in biology-immunology from Johns Hopkins University and completed Harvard Business School's PMD.

srobertson@biospartners.com

Stephen Phillips· Vice President· Fort Worth, Texas, United Statesin

Vice President at Bios Partners focused on diligence, negotiations, portfolio management, and investor relations. Previously VP at Moorea Capital family office. Holds an MBA from Dallas Baptist University.

sphillips@biospartners.com

Tim Van Treuren· Principal· Fort Worth, Texasin

Joined Bios Partners in 2019, managing deal flow and leading scientific due diligence. Serves on the board of Bobcat Bio. Holds a PhD in Biomedical Sciences with an emphasis in Cancer Biology from UNT Health Science Center.

tvantreuren@biospartners.com

Troy Osborn· Investor Relations· Austin, Texas, United Statesin

CFO at Bios Partners since June 2019. Previously an auditor at KPMG specializing in private equity and hedge fund accounting. Holds a Master's in Accounting from Abilene Christian University.

ir@biospartners.com

Blake Pate· Analyst· Dallas, Texasin 𝕏

Vice President of Investments at Bios Partners since May 2019, focused on due diligence and deal flow, and also VP of Bios Research. Holds a BS in Biology and a Master of Science in Biotechnology from Johns Hopkins University, and is a Network Partner for 2048 Ventures.

bpate@biospartners.com

Daniel Schwarz· COO and CFO· Brno, South Moravia, Czechiain

dschwarz@biospartners.com

Don Short· Chief Financial Officer· Canadain

Head of Venture Equity and Chief Compliance Officer for InvestX Financial (Canada), overseeing the investment team's five-factor model for late-stage private companies. A CFA and registered portfolio manager with 30+ years of experience, previously CIO at Qwest Investment Fund Management.

Giacomo Piccinini· Vice President· Milan, Lombardy, Italyin

Giacomo Piccinini is an Investment Manager at Panakes Partners. Trained as a bioengineer, he has experience in venture capital, the life science sector, and the startup ecosystem, with a focus on healthcare innovation and life science.

giacomo.piccinini@panakes.it

Patrick Browning· Vice President· Fort Worth, Texasin

Patrick Browning is an Executive Director and Banker at J.P. Morgan Private Bank, where he advises family offices, business owners, investment professionals, and ultra-high-net-worth families in the Fort Worth area. Drawing on prior experience at a single-family office and private capital firm, he addresses client needs including wealth structuring, liquidity management, and concentrated asset planning. He facilitates access to J.P. Morgan's Commercial Bank, Investment Bank, and related business lines.

Roni Meintjes· Analyst· Dallas, Texas

Steven Hood· Vice President· Fort Worth, Texasin

What they invest in

from 18 of 19 portfolio companies

Biotech ×9Healthtech ×9AI & Machine Learning ×4Medical Devices ×4Enterprise Software ×3SaaS ×3Cloud Computing ×2Developer Tools ×2

HQs:United States×18

Investments · 19 tracked

founders shown can be your intro path

By year:2025 · 1 2024 · 1 2023 · 1 2022 · 2 2021 · 2 2020 · 1 2019 · 1 2018 · 2 2015 · 213 dated

Actuate Therapeuticsactuatetherapeutics.com in 𝕏NASDAQ: ACTUSep 2015 · $21.7M

Actuate Therapeutics is a clinical-stage biopharmaceutical company developing elraglusib, a small-molecule GSK-3β inhibitor designed to treat difficult-to-treat cancers including pancreatic, melanoma, lung, and pediatric cancers through intravenous injection and oral tablet formulations.

BiotechFort Worth, US

Daniel Schmitt(President & Chief Executive Officer)Paul Lytle(Executive Officer)inAndrew Mazar(Executive Officer)

Board Todd Thomson(Director)inRoger Sawhney(Director)Jason Keyes(Director)

Board seatAaron G.L. Fletcher Aaron G.L. Fletcher Leslie W. Kreis, Jr.· per SEC Form D

Co-investorsIllinois Ventures Kairos Venture Investments, Llc Bios DEFTA Partners Tech Coast Angels

Azitraazitrainc.comNYSE: AZTRSep 2020 · $17M

Azitra is a clinical-stage biopharmaceutical company developing genetically engineered bacteria and proteins for treating skin diseases through precision dermatology.

AI & Machine LearningBiotechHealthtechFarmington, US

Francisco D. Salva(President and Chief Executive Officer)inAzim Munivar(Executive Officer, Director, Promoter)

Board seat Stella Robertson Travis Whitfill· per SEC Form D

Co-investorsConnecticut Innovations KdT Ventures Leaps by Bayer

Cue Biopharmacuebiopharma.com inNASDAQ: CUENov 2022SEC filingmedium confidence

Cue Biopharma is a precision immunotherapy company developing engineered therapies targeting allergic and autoimmune diseases.

BiotechHealthtechMedical DevicesBoston, US

Daniel Baker(Executive Officer)Colin Sandercock(Executive Officer)in Dominic Borie(Chief Medical Officer and Head of Research and Development)in Sumita Ray(Executive Officer)inMichael Meluzio(Executive Officer)inRodolfo Chaparro(Vice President, Head of Immunology)in

Board seat Aaron G.L. Fletcher· per SEC Form D · $30M raise · filed Nov 2022

In8Bioin8bio.com inNASDAQ: INABMay 2018SEC filingmedium confidence

IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell therapies for solid and hematological tumors using its DeltEx platform (allogeneic, autologous, iPSC, and genetically modified approaches).

BiotechHealthtechNew York, US

Lawrence Lamb(Scientific Founder & Chief Scientific Officer)in William Ho(Founder & Chief Executive Officer)inKate Rochlin(Executive Officer)in Patrick McCall(Executive Officer)in Travis Whitfill(Director)inMelissa Beelen(Executive Officer)

Board seat Travis Whitfill· per SEC Form D · $35M raise · filed Sep 2020

Equipment Shareequipmentshare.com in 𝕏NASDAQ: EQPTSeed

EquipmentShare provides construction equipment rentals and fleet management technology for builders and contractors.

Construction TechIoTPropTechSaaSColumbia, US

Brad Siegler(Founder)inJeff Lowe(Founder)in Jabbok Schlacks(Founder)in William Schlacks(President)inWilly Schlacks(Founder)Alex Levy(Investor)in

Co-investorsY Combinator Amity Ventures Depth Ventures Evolution VC Partners FundersClub G Squared +28 more

Trefoil Therapeuticstrefoiltherapeutics.com inApr 2025✓ verified

Trefoil Therapeutics is a clinical-stage biotechnology company developing therapeutic agents for corneal diseases.

BiotechHealthtechMedical DevicesSan Diego, US

David Eveleth(Executive Officer, Director)in Schalon Newton(Executive Officer)in

Board Christy Shaffer(Director)inRalph Bradshaw(Director)

Board seat Stella Robertson· per SEC Form D

Co-investorsExSight Ventures Hatteras Venture Partners Solasta Ventures Access Biotechnology Correlation Ventures FemHealth Ventures +1 more

ONL Therapeuticsonltherapeutics.com inMar 2023✓ verified

ONL Therapeutics is a clinical-stage biopharmaceutical company developing therapies to preserve sight by preventing Fas-mediated death of retinal cells, a cause of vision loss and blindness.

BiotechHealthtechMedical DevicesAnn Arbor, US

David Zacks(Co-Founder & Chief Scientific Officer)in David Esposito(Executive Officer, Director)inConstance Chang(Executive Officer)John K Freshley(Executive Officer, Director)in Jeffrey A Jamison(Executive Officer)in

Board Aaron Fletcher(Director)in

Co-investorsExSight Ventures Invest Michigan Novartis Venture Fund Visionary Ventures InFocus Capital Partners, LLC Johnson & Johnson Innovation – JJDC +3 more

410 Medical410medical.com in 𝕏Aug 2018SEC filingmedium confidence

410 Medical makes LifeFlow, a hand-operated rapid infuser that lets clinicians quickly deliver blood or fluids to critically ill patients needing volume resuscitation.

HardwareHealthtechMedical DevicesDurham, US

Mark Donald Piehl(Executive Officer, Director)KYLE CHENET(Executive Officer, Director)in

Board JEFF TERRELL(Director)inSTANLEY D. LYNALL(Director)FRED GOLDWATER(Director)inMAYANK TANEJA(Director)in

Board seat Travis Whitfill· per SEC Form D · $4M raise · filed Aug 2018

Co-investorsBallad Ventures CU Healthcare Innovation Fund Duke Capital Partners OSF Ventures Wellstar Wolfpack Investor Network +2 more

Lung Therapeuticslungtx.comMar 2022

BiotechAustin, US

James Brian Windsor(President and CEO)Steven Idell(Director)

Board Aaron Fletcher(Director)inJoseph Woelkers(Director)Robert Mills(Director)

Board seat Aaron G.L. Fletcher· per SEC Form D

Co-investorsUT Horizon Fund

Actuateactuate.ai in 𝕏May 2019 · $21.7M

Actuate provides AI-based video analytics that turn existing IP cameras and NVRs into a security detection system, offering real-time alerts for threats such as intruders, loitering, guns, and crowds.

AI & Machine LearningCloud ComputingCybersecurityGovTechSaaS

Sonny Tai(Co-Founder)inKen Francis(CEO)in

Co-investorsBling Capital Dorm Room Gray Line Partners MetaProp MetaProp Ventures Scribble Ventures +4 more

Bluesmartbluesmart.comSeedAcquired

Bluesmart manufactures connected luggage with integrated app controls for travelers seeking location tracking and mobile device management features.

ConsumerHardwareNew York City, US

Alejo Verlini(CPO)in Diego Saez Gil(CEO)in Martin Diz(CTO)inTomi Pierucci(CEO)Brian Chen(Vice President of Operations)Pablo Orlando(COO)in

Co-investorsCota Capital FundersClub German Ventures Mind the Seed - MTS Fund Y Combinator ACE & Company +18 more

Call9callnine.comSeries ADefunct

Call9 provides emergency and palliative care to patients in skilled nursing facilities by combining onsite clinical care specialists with remote emergency medicine physicians who evaluate and treat patients via a proprietary platform, reducing response times from an average of 64 minutes to immediate care.

HealthtechNew York City, US

Celina Tenev(Founder)Timothy Peck(CEO)XiaoSong Mu(CTO)Chris Stringfellow

Co-investorsFundersClub Y Combinator Great Oaks Venture Capital Hillcrest Venture Partners Index Ventures Joe Lonsdale +8 more

Convoxconvox.com in 𝕏Seed · Aug 2015Acquired

Convox provides a platform for deploying and managing cloud-native applications across multiple cloud providers including AWS, Google Cloud, and Azure.

Cloud ComputingData & InfrastructureDeveloper ToolsEnterprise SoftwareAtlanta, US

David Dollar(CEO)in Noah Zoschke(CTO)inMatt Manning(Founder)in

Co-investorsCurious Capital Garage Capital Heavybit Y Combinator Inovia Capital Prosperity7 Ventures +4 more

Encore Vision Inc.encorevisionusa.com

Encore Vision supplies eyewear frames and operates a full-service digital optical lab, offering combined frame-and-lens solutions to eyecare practices.

HealthtechRetail TechFort Worth, US

Evelyn Blake(Executive Officer)William R. Burns(Executive Officer, Director)in

BoardLes Kreis(Director)Robert Willard(Director)John Hunkeler(Director)Adrienne Graves(Director)

Co-investorsCowtown Angels

Pomellopomello.comSeedAcquired

Pomello provides organizational culture assessment software that evaluates team dynamics and integrates with recruitment workflows to identify job candidates likely to succeed within a company's specific culture.

AI & Machine LearningEnterprise SoftwareHR TechSaaSSan Francisco, US

Oliver Staehelin(Founder)in Catherine Spence(Founder)inXian Ke

Co-investorsSoma Capital Y Combinator China Growth Capital Haystack New Enterprise Associates (NEA)PreAngel Fund

Stream Biomedicalstreambiomedical.comDec 2021

Stream Biomedical is a clinical-stage biotechnology company developing LG3, a biologic derived from a natural repair protein intended to protect and restore the brain by activating its repair systems.

BiotechDeep TechHealthtechHouston, US

H. Davis Adkisson(Chief Scientific Officer)inChris Garabedian(Director)William Schwieterman(Board of Directors)Fred Callori(Director)

Board Amanda De La Garza(Director)in

Co-investorsCowtown Angels

Yhatyhat.com inSeedAcquired

Yhat provided a platform for managing the complete lifecycle of data science projects, from model development through deployment.

AI & Machine LearningDeveloper ToolsEnterprise SoftwareNew York City, US

Austin Ogilvie(CEO)inGreg Lamp(Founder)in Ryan O'Neil(Lead Engineer)in

Co-investorsboldstart ventures Contour Venture Partners Longley Capital RRE Ventures Y Combinator Collaborative Fund +4 more

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

BobcatBioSIRPant Immunotherapeutics, Inc.

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.

Exits · 9

5 IPOs · 4 acquisitions · showing 5

Actuate TherapeuticsNASDAQ: ACTUAzitraNYSE: AZTRCue BiopharmaNASDAQ: CUEIn8BioNASDAQ: INABEquipment ShareNASDAQ: EQPT

Portfolio news

latest coverage across their companies

Is EquipmentShare.com (EQPT) Cheap Following Its 2026 Outlook Raise And $500 Million Buyback? - Simply Wall St News

Equipment Share · simplywall.st · Jul 14, 2026

410 Medical Raises $12M in Funding

410 Medical · finsmes.com · Jul 14, 2026

Biotech firm Cue Biopharma lines up $50M to push its immune disorder drugs

Cue Biopharma · stocktitan.net · Jul 10, 2026

Azitra, Inc. CEO Issues Letter to Shareholders Detailing Strategic Reorientation Initiatives and Outlook for 2026 and Beyond

Azitra · prnewswire.com · Jun 17, 2026

Public market activity · per SEC filings

what is this? ⓘ

10 insider ownership filings (Forms 3/4/5)

at ACTUATE THERAPEUTICS, INC. (ACTU), IN8BIO, INC. ([INAB), IN8BIO, INC. (INAB), COGNITION THERAPEUTICS INC (CGTX)

From the firm's own SEC EDGAR filings — stakes and insider roles in public companies, typically portfolio companies after an IPO. Not a portfolio list published by the firm.

Frequently asked questions

How many investments has Bios Partners made?: Bios Partners has 19 tracked investments, 9 of which have exited, including 1 dated in the last 24 months.
What stage does Bios Partners invest at?: Bios Partners invests at the Seed, Series A, Series B, Series C, Growth stages.
What sectors does Bios Partners focus on?: Bios Partners focuses on Biotech, Healthtech, Medical Devices.
Where is Bios Partners located?: Bios Partners is headquartered in Fort Worth, US.

Similar investors

ACT Venture Capital

ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.

$1.1M – $16.2M

Amadeus Capital Partners

Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.

$50K – $12.7M

B Capital Group

B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.

$10M – $50M

Capricorn Venture Partners

Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.

$270K – $10.8M

DCVC (Data Collective)

DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.

$5M – $25M